Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Triple combination therapy group

Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.

DRUG

Premixed insulin therapy group

Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM

Trial Locations (1)

510300

The Pearl River Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

The Sixth Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Third Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Peking University Shenzhen Hospital

OTHER

collaborator

Dongguan Kanghua Hospital

OTHER

collaborator

First People's Hospital, Shunde China

OTHER

collaborator

The First Affiliated Hospital of Guangdong Pharmaceutical University

OTHER

collaborator

The Fifth Affiliated Hospital of Zunyi Medical College

OTHER

collaborator

Shenzhen Sixth People's Hospital

OTHER

lead

Zhujiang Hospital

OTHER

NCT03700801 - Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy | Biotech Hunter | Biotech Hunter